drugset
drugset / Trial / NCT00162058

A Phase II Study of DMP 115 to Assess Focal Liver Lesions

NCT00162058 ↗

Phase 2 Completed 80 enrolled Lantheus Medical Imaging
Non-randomizedSingle-groupOpen-label

Summary

To determine the optimal dose of DMP 115 to image liver lesions and to assess whether contrast can improve the detection of focal liver lesions.

Timeline

Start
2004-03
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Peflutren Unknown — —

Indications

liver disorder